<?xml version="1.0" encoding="utf-8" ?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:atom="http://www.w3.org/2005/Atom">
	<channel>
		<title>PR.com Press Releases: electroCore News</title>
		<link>https://www.PR.com/</link>
		<description>Latest news releases from PR.com for electroCore.</description>
		<lastBuildDate>Sun, 15 Nov 2026 23:46:42 -0500</lastBuildDate>
		<copyright>&#169; 2026 PR.com</copyright>
		<ttl>60</ttl>
		<language>en-us</language>
		<image>
			<url>https://www.PR.com/images/logo_white.jpg</url>
			<title>PR.com Press Releases: electroCore News</title>
			<link>https://www.PR.com/</link>
			<width>68</width>
			<height>69</height>
			<description>PR.com provides press release distribution, and is a unique directory of businesses, products and services. Find full company profiles.</description>
		</image>
		<atom:link href="https://www.pr.com/rss/press-releases-2/314178.xml" rel="self" type="application/rss+xml" />
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/695242</guid>
			<title>Mount Sinai Beth Israel Receive Award from the Department of Defense to Study Gulf War Illness with electroCore’s Non-Invasive Vagus Nerve Stimulation Therapy</title>
			<pubDate>Thu, 17 Nov 2016 12:23:52 -0500</pubDate>
			<description>The Pain &#38; Fatigue Study Center at Mount Sinai Beth Israel in New York has been awarded a United States Army Medical Research grant to conduct a study into the treatment of veterans of the 1990-1991 Gulf War who have Gulf War Illness using electroCore&#8217;s non-invasive vagus nerve stimulation (nVNS) therapy gammaCore. The $703,272 grant will be used to fund a randomized clinical trial involving more than 40 [PR.com]</description>
			<link>https://www.pr.com/press-release/695242</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/692300</guid>
			<title>Presentation from electroCore Shows That Healthcare Costs for Patients with a Primary Headache Diagnosis Cost Four Times More Than a Healthy Patient Due to Comorbidities</title>
			<pubDate>Sat, 22 Oct 2016 03:00:00 -0400</pubDate>
			<description>Research presented at the Academy of Managed Care Pharmacy (AMCP) Nexus in early October in Washington, DC, showed that 60 percent of adult patients who were diagnosed with primary headache had one or more comorbidities which raised the average annual cost of their healthcare to over $20,000. This compares with the annual average healthcare cost of a US adult patient of $5,300.  The research, by GNS Healthcare, showed [PR.com]</description>
			<link>https://www.pr.com/press-release/692300</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/687175</guid>
			<title>The Journal Headache Reports That electroCore’s Non-Invasive Vagus Nerve Stimulator is an Effective Bioelectric Medicine for Episodic Cluster Headache</title>
			<pubDate>Wed, 14 Sep 2016 03:00:00 -0400</pubDate>
			<description>In a multi-centered, sham-controlled study conducted in the United States, episodic cluster headache patients using the gammaCore non-invasive vagus nerve stimulation device (nVNS) had a significant and clinically meaningful benefit within 15 minutes of the treatment of the attack, as compared with the sham treatment, and that this benefit was sustained for over an hour.  The paper also reported that nVNS is well [PR.com]</description>
			<link>https://www.pr.com/press-release/687175</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/675660</guid>
			<title>ElectroCore’s Non-Invasive Vagus Nerve Stimulation (nVNS) Demonstrates Efficacy in Preventing Cluster Headache and Menstrual Migraine</title>
			<pubDate>Fri, 17 Jun 2016 03:00:00 -0400</pubDate>
			<description>The results of two studies, presented at the American Headache Society (AHS) Science Meeting last weekend in San Diego, show that using electroCore&#8217;s non-invasive vagus nerve stimulation (nVNS) therapy, gammaCore&#174;, is effective at preventing both cluster headache and menstrual migraine. Cluster headache is considered one of the most painful conditions known to medical science with more than three hundred and [PR.com]</description>
			<link>https://www.pr.com/press-release/675660</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/674283</guid>
			<title>Seven Presentations on electroCore’s Treatment for Cluster Headache and Migraine Will Feature at American Headache Society Science Meeting</title>
			<pubDate>Wed, 08 Jun 2016 03:00:00 -0400</pubDate>
			<description>Recent clinical and preclinical results using electroCore&#8217;s non-invasive vagus nerve stimulation (nVNS, gammaCore&#174;) therapy in the treatment and prevention of primary headache are the subject of seven presentations at the American Headache Society (AHS) Science Meeting being held at San Diego next week (June 9th to 12th).  The seven accepted abstracts are based on work conducted at universities across the US and [PR.com]</description>
			<link>https://www.pr.com/press-release/674283</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/671405</guid>
			<title>electroCore&#039;s GammaCore is Both Effective and Cost Effective for the Treatment of Cluster Headache</title>
			<pubDate>Wed, 18 May 2016 03:00:00 -0400</pubDate>
			<description>A paper in the Journal of Headache and Pain reports that non-invasive stimulation of the vagus nerve (nVNS) is a cost effective therapy for cluster headache. These findings were based on reductions in medication use and improvements in quality of life. The publication also notes that further economic benefits would have been found had reduced visits to clinics been taken into account.  Cluster headache, which is [PR.com]</description>
			<link>https://www.pr.com/press-release/671405</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/666160</guid>
			<title>NICE Provides Positive Guidance on electroCore’s gammaCore Treatment for the Prevention and Acute Treatment of Migraine and Cluster Headache</title>
			<pubDate>Sat, 09 Apr 2016 03:00:00 -0400</pubDate>
			<description>The UK&#8217;s National Institute of Health and Care Excellence (NICE) has published guidance that electroCore&#8217;s non-invasive vagus nerve stimulation treatment (gammaCore) for the prevention and acute treatment of migraine and cluster headache is safe and can now be used in the NHS.  The guidance issued by NICE showed that among the five separate clinical trials of gammaCore they reviewed, many patients experienced [PR.com]</description>
			<link>https://www.pr.com/press-release/666160</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/632074</guid>
			<title>Dr Nader N Youssef Appointed Chief Medical Officer of electroCore</title>
			<pubDate>Sun, 09 Aug 2015 03:00:00 -0400</pubDate>
			<description>Dr Nader N Youssef has been appointed Chief Medical Officer of electroCore, the US based electroceutical healthcare company. Nader brings more than 15 years of clinical, academic, and industry research experience to electroCore.  He was previously Executive Director GI Global Clinical Development and Medical Affairs for NPS Pharmaceuticals including responsibility for overall regulatory and development strategy. During [PR.com]</description>
			<link>https://www.pr.com/press-release/632074</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/628844</guid>
			<title>The Journal of Headache and Pain Reports That electroCore’s Non-Invasive Vagus Nerve Stimulation (nVNS) Treatment is Effective in Migraines</title>
			<pubDate>Fri, 17 Jul 2015 03:00:00 -0400</pubDate>
			<description>-- 65% of the study participants reported pain relief(1) by 2 hours after treatment, with 56% already reporting pain relief by one hour, and 35% were pain free by one hour  -- Authors stated that nVNS was safe, well tolerated and effective in many patients and may reduce medication overuse and medication associated adverse events  The study which is in the July edition of the The Journal of Headache and Pain(2) reports [PR.com]</description>
			<link>https://www.pr.com/press-release/628844</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/622821</guid>
			<title>Patrick Fabbio Appointed Chief Financial Officer at electroCore</title>
			<pubDate>Sat, 06 Jun 2015 03:00:00 -0400</pubDate>
			<description>Patrick Fabbio has been appointed Chief Financial Officer of electroCore, the US based electroceutical healthcare company. Pat, who was previously VP Finance for NPS Pharmaceuticals, has more than 20 years of financial leadership experience in both public and private life science and pharmaceutical companies.  During his three years with NPS, he led the build-out of the global finance department and supported the $5.2 [PR.com]</description>
			<link>https://www.pr.com/press-release/622821</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/620784</guid>
			<title>Patients Embrace gammaCore - the New Non Pharmacologic Treatment for Migraines</title>
			<pubDate>Sat, 23 May 2015 03:00:00 -0400</pubDate>
			<description>A poster at the International Headache Congress(1), in Valencia, reports on a study which examined patients&#8217; attitude to electroCore&#8217;s non-invasive vagus nerve stimulation (nVNS) treatment for migraines.  The research by the Headache Centre in Rome(2) asked 60 patients why they started treatment with the gammaCore nVNS device. The majority of patients (67.3%) initiated nVNS therapy due a resistance to standard [PR.com]</description>
			<link>https://www.pr.com/press-release/620784</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/620172</guid>
			<title>Presentation at International Headache Congress Shows electroCore’s Chronic Cluster Headache Treatment to be Cost-Effective</title>
			<pubDate>Wed, 20 May 2015 03:00:00 -0400</pubDate>
			<description>&#183; electroCore&#8217;s gammaCore non-invasive vagus nerve stimulation (nVNS) therapy improves quality of life when added to standard of care (SOC) &#183; gammaCore is cost-effective compared to other treatment options &#183; gammaCore reduces acute medication usage, resulting in a 30% decrease in cost.  A poster at the International Headache Society meeting in Valencia, Spain1 demonstrated that treatment with [PR.com]</description>
			<link>https://www.pr.com/press-release/620172</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/617214</guid>
			<title>ElectroCore’s Non-Invasive Vagus Nerve Stimulation Therapy Shown to be Safe and to Produce No Meaningful Cardiac Adverse Effects</title>
			<pubDate>Thu, 30 Apr 2015 03:00:00 -0400</pubDate>
			<description>At the 67th American Academy of Neurology meeting in Washington, DC, last week a poster presentation showed that electroCore&#8217;s non-invasive vagus nerve stimulation (nVNS) therapy does not cause any meaningful cardiovascular adverse effects in patients with asthma. The poster presentation, reported on the cardiac effects of nVNS in asthma patients using nVNS to treat acute bronchospasm. This study further reinforces [PR.com]</description>
			<link>https://www.pr.com/press-release/617214</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/612701</guid>
			<title>ElectroCore: a Finalist in the 2015 FT ArcelorMittal Boldness in Business Awards Technology Category</title>
			<pubDate>Wed, 01 Apr 2015 03:00:00 -0400</pubDate>
			<description>At the annual FT ArcelorMittal Boldness in Business awards held in London last week electroCore was one of six finalists in the &#8216;Technology&#8217; category, in a competition that included over 250 companies, which Open Garden won for its FireChat digital app(1).  ElectroCore, a world leader in electroceuticals was nominated for its pioneering development of gammaCore, the non-invasive delivery of vagus nerve [PR.com]</description>
			<link>https://www.pr.com/press-release/612701</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/608508</guid>
			<title>Clinical Study Published in Neurology Finds That Electrocore’s Non-Invasive Vagus Nerve Stimulation is Effective in Treating Cluster Headaches</title>
			<pubDate>Thu, 05 Mar 2015 03:00:00 -0500</pubDate>
			<description>An open-label study published in the journal Neurology, reports that electroCore’s non-invasive Vagus Nerve stimulation (nVNS) device, gammaCore, is practical and effective as an acute and preventative treatment in cluster headache. [PR.com]</description>
			<link>https://www.pr.com/press-release/608508</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/603138</guid>
			<title>A Review in the European Journal of Neurology Confirms That electroCore’s nVNS is Not Only Safe But Could be Effective Across a Wide Range of Conditions</title>
			<pubDate>Fri, 30 Jan 2015 03:00:00 -0500</pubDate>
			<description>According to a review in the European Journal of Neurology electroCore&#039;s non-invasive vagus nerve stimulation therapy is not only safe but could be effective for a wide range of conditions. [PR.com]</description>
			<link>https://www.pr.com/press-release/603138</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/594423</guid>
			<title>electroCore CEO, JP Errico, Emphasizes the Importance of Early Collaboration with Patients Group, Providers, and Payors When Introducing Innovative Technologies</title>
			<pubDate>Fri, 28 Nov 2014 03:00:00 -0500</pubDate>
			<description>JP Errico, founder and CEO of electroCore, speaking at The FT Global Pharmaceutical and Biotechnology Conference in London last week, emphasized the importance of working with each of the major stakeholders, i.e., patients and their advocates, key opinion-leading physicians, and decision-makers within the payor community at the earliest opportunity, particularly in regards to innovative and disruptive technology such as [PR.com]</description>
			<link>https://www.pr.com/press-release/594423</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/588635</guid>
			<title>Trial Reported in Headache and Pain Journal Further Confirms the Effectiveness of electroCore’s Non-Invasive Vagus Nerve Stimulation Treatment for Headache</title>
			<pubDate>Sat, 25 Oct 2014 03:00:00 -0400</pubDate>
			<description>Preliminary results of an open-label trial carried in the journal of Headache and Pain reported that a single treatment with electroCore&#8217;s hand held non-invasive vagus nerve stimulation (nVNS) device gammaCore, completely resolved 44.8% of migraines within 30 minutes, with an additional 11.4% experiencing moderate benefits (incomplete resolution of their headaches) by 2 hours. This result follows two presentations [PR.com]</description>
			<link>https://www.pr.com/press-release/588635</link>
			<dc:creator>electroCore</dc:creator>
		</item>
		<item>
			<guid isPermaLink="true">https://www.pr.com/press-release/583193</guid>
			<title>Randomized Data Presented at International Headache Meeting (EHMTIC)) Shows Gammacore Significantly Reduces Cluster Headache Attack Frequency*</title>
			<pubDate>Thu, 25 Sep 2014 03:00:00 -0400</pubDate>
			<description>The biannual European Headache and Migraine Trust International Conference (EHMTIC) meeting concluded yesterday in Copenhagen, where more than 900 neurologists and other headache specialists came to hear about the latest advances in managing severe headache conditions, including electroCore&#8217;s gammaCore therapy. The attendees heard that a large scale randomized clinical trial of the gammaCore therapy in chronic [PR.com]</description>
			<link>https://www.pr.com/press-release/583193</link>
			<dc:creator>electroCore</dc:creator>
		</item>
	</channel>
</rss>